학술논문
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Document Type
Article
Author
Wei, Xiaoting; Zou, Zhengyun; Zhang, Weizhen; Fang, Meiyu; Zhang, Xiaoshi; Luo, Zhiguo; Chen, Jing; Huang, Gang; Zhang, Peng; Cheng, Ying; Liu, Jiwei; Liu, Jiyan; Zhang, Junping; Wu, Di; Chen, Yu; Ma, Xiaobiao; Pan, Hongming; Jiang, Renbing; Liu, Xinlan; Ren, Xiubao; Tian, Hongqi; Jia, Zhongwei; Guo, Jun; Si, Lu
Source
In European Journal of Cancer May 2024 202
Subject
Language
ISSN
0959-8049